• Castle Biosciences Chief Commercial Officer Tobin W Juvenal sold 6,116 shares of common stock, reducing his direct holdings to 32,737 shares.
• The November 9, 2026, sale comprised 3,288 shares at $32.67 per share.
• A further 2,828 shares were sold on November 11, 2026, at $35.044 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-073402), on November 12, 2026, and is solely responsible for the information contained therein.